備鎮心®糖衣錠75毫克 (法國廠)

国: 台湾

言語: 中国語

ソース: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有効成分:

DIPYRIDAMOLE

から入手可能:

裕利股份有限公司 台北市松山區南京東路四段126號10樓，10樓之1-3 (22853066)

ATCコード:

B01AC07

医薬品形態:

錠劑

構図:

DIPYRIDAMOLE (2412400400) MG

パッケージ内のユニット:

鋁箔盒裝

クラス:

製　劑

処方タイプ:

須由醫師處方使用

製:

DELPHARM REIMS 10 RUE COLONEL CHARBONNEAUX, 51100 REIMS, FRANCE FR

治療領域:

dipyridamole

適応症:

對於慢性狹心症之治療可能有效。

製品概要:

有效日期: 2027/02/20; 英文品名: Persantin 75mg Sugar-Coated Tablets

承認日:

2012-02-20

情報リーフレット

Druckfarben
Datum/Signatur
KORREKTUR ERBETEN
DRUCKFREIGABE
Auftrags-Nr.
21/0
erstellt
10.03.21
WO
Produktbezeichnung
PERSANTIN 75MG
SUGAR-COATED TABLETS
TW
Maße in mm
160 X 580
PACKAGE INFORM.
PRXX
Artikel-Nr.
312325GI-01
CODE 20
Druckfarben
PANTONE BLACK C
kleinste Schriftgröße
10 PT
VORDERSEITE
312325GI-01
xxx
PERSANTIN® 75 MG
SUGAR-COATED TABLETS
COMPOSITION
[Active ingredient] Dipyridamole
[Dosage form, strength]
1 sugar-coated tablet contains
2,6-bis(diethanolamino)-4,8-dipiperidino-
pyrimido(5,4-d)-
pyrimidine (= dipyridamole)
75 mg
Excipients
maize starch dried, starch soluble, calcium
hydrogen phosphate anhydrous, colloidal
silica anhydrous, magnesium stearate, talc,
sucrose, macrogol 6000, acacia, yellow
orange S, titanium dioxide, beeswax white,
carnauba wax
CLINICAL PHARMACOLOGY
Dipyridamole inhibits the uptake of
adenosine into erythrocytes, platelets and
endothelial cells in vitro and in vivo; the
inhibition amounts to 80% at its maximum
and occurs dose-dependently at therapeutic
concentrations (0.5 – 2 mcg/ml).
Consequently,there is an increased
concentration of adenosine locally to act on
the platelet A2-receptor, stimulating platelet
adenylate cyclase, thereby increasing platelet
cAMP levels. Thus, platelet aggregation in
response to various stimuli such as PAF,
collagen and ADP is inhibited. Reduced
platelet aggregation reduces platelet
consumption towards normal levels. In
addition, adenosine has a vasodilator effect
and this is one of the mechanisms by which
dipyridamole produces vasodilation.
Following an I.V. does of dipyridamole tablet,
the peak plasma concentration is reached
about one hour. After I.V. administration, the
beta phase has a half-life of approximately
40 minutes, and final terminal elimination
phase has a half-life of about 13 hours.
Protein binding of dipyridamole is about
97-99%.
It is metabolized in liver, and the metabolites
are mostly (about 95%) excreted via the bile
into the feces.
INDICATIONS
May be effective on the treatment of chronic
angina
DOSAGE AND ADMINIST